Fox Run Management’s Aldeyra Therapeutics ALDX Stock Holding History

Fox Run Management’s Portfolio ALDX Stock Details ALDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-90,964	Closed	-$153K	–	907
2026 Q1	$153K	Buy	90,964 +69,981	+334%	+$307K	0.03%	797
2025 Q4	$109K	Buy	+20,983	New	+$108K	0.02%	855
2025 Q2	–	Sell	-22,912	Closed	-$132K	–	831
2025 Q1	$132K	Buy	+22,912	New	+$135K	0.02%	845
2024 Q4	–	Sell	-19,002	Closed	-$102K	–	841
2024 Q3	$102K	Buy	+19,002	New	+$90.4K	0.02%	739
2023 Q4	–	Sell	-33,519	Closed	-$224K	–	704
2023 Q3	$224K	Buy	+33,519	New	+$249K	0.07%	532
2023 Q2	–	Sell	-23,317	Closed	-$232K	–	661
2023 Q1	$232K	Buy	23,317 +10,635	+84%	+$75.2K	0.08%	475
2022 Q4	$88.3K	Buy	+12,682	New	+$72.5K	0.04%	570

Other funds holding ALDX

KCM

Knoll Capital Management Miami, Florida $179M AUM 63.61% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

KCM

Kingdon Capital Management New York $976M AUM 66.76% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

6CM

683 Capital Management New York $2.04B AUM 94.26% 1-Year Est. Return

Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return

Fox Run Management's ALDX Position: Q2 2026 in Review

Fox Run Management sold out of Aldeyra Therapeutics (ALDX) in Q2 2026, closing a stake of 90,964 shares — an estimated $153K sold.

Fox Run Management first reported a position in ALDX in Q4 2022 and held it in 7 quarters. The position peaked at $232K in Q1 2023. 108 funds tracked by Wall St. Rank hold ALDX as of Q2 2026.

Fox Run Management reported no remaining Aldeyra Therapeutics position as of Q2 2026 after selling out during the quarter.
Fox Run Management sold 90,964 Aldeyra Therapeutics shares in Q2 2026, an estimated $153K.
Fox Run Management first reported a position in Aldeyra Therapeutics in Q4 2022 and held it in 7 quarters.
Fox Run Management's Aldeyra Therapeutics position peaked at $232K in Q1 2023.
108 funds tracked by Wall St. Rank held Aldeyra Therapeutics as of Q2 2026.

Based on Fox Run Management's 13F filing for Q2 2026, filed 4 Aug 2026.